Red Clover Isoflavones in Postmenopausal Women With Urge Urinary Incontinence and Overactive Bladder

Not Applicable

Completed

• Conditions: Urge Incontinence; Overactive Bladder
• Interventions: Dietary Supplement: Red Clover Extract (RCE); Other: Placebo (PL)

• Registration Number: NCT05013593
• Lead Sponsor: Vendsyssel Hospital

Brief Summary

The purpose of this study is to investigate the effect of red clover isoflavones in postmenopausal women with and without urge urinary incontinence and overactive bladder

Detailed Description

Not available

Study Timeline

• Study Start: 2019-07-15
• Study First Submitted: 2021-08-03
• Study First Submitted QC: 2021-08-11
• Study First Posted: 2021-08-19
• Primary Completion: 2021-10-20
• Study Completion: 2021-10-20
• Status Verified: 2023-04
• Last Update Submitted: 2023-04-25
• Last Update Posted: 2023-04-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 108

Inclusion Criteria

• Postmenopausal (more than 5 years since last menstruation)
• Read and understand Danish

Exclusion Criteria

• Participants receive treatment with estrogen both oral, transdermal, and topical within three months prior to inclusion in the study
• Participants take estrogen-like compounds (isoflavones) three months prior to inclusion in the study
• Participants take prebiotic and/or probiotic supplements within three months prior to study inclusion
• Receive antibiotics (any) within three months prior to inclusion in the study
• Recurrent urinary tract infections (defined as ≥ 2 infections in the last six months or ≥ 3 infections during the last year)
• Acute urinary tract infection defined as positive urine culture and symptoms of acute cystitis
• Previous or current diseases of the digestive and/or urinary systems evaluated by PI (including, but not limited to inflammatory bowel disease (IBD) and cancer)
• Current or prior suffering from breast, ovary, and/or endometrial cancer
• Use hormone spiral within the last 5 years if they are under 60 years
• Hysterectomy before cessation of menstrual periods if the women are below the age of 60

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Symptomatic RCE	Red Clover Extract (RCE)	Bladder symptomatic group receiving red clover extract containing the two isoflavones formononetin and biochanin A. Isoflavone amount is 57.45 mg isoflavones daily (55.84 mg aglycones daily), in 70 ml red clover extract (35 ml twice daily, morning and evening with a meal)
Healthy RCE	Red Clover Extract (RCE)	Healthy group without bladder symptoms receiving red clover extract containing the two isoflavones formononetin and biochanin A. Isoflavone amount is 57.45 mg isoflavones daily (55.84 mg aglycones daily), in 70 ml red clover extract (35 ml twice daily, morning and evening with a meal)
Healthy PL	Placebo (PL)	Healthy group without bladder symptoms receiving placebo
Symptomatic PL	Placebo (PL)	Bladder symptomatic group receiving placebo

Primary Outcome Measures

Name	Time	Method
Change in baseline microbiota composition at three months follow-up	From baseline to three months follow-up	The microbiota composition is analyzed using sequencing of bacterial DNA. Comparison of healthy women without bladder symptoms receiving RCE (healthy RCE) at baseline to three months follow-up compared to controls (healthy PL) from baseline to follow-up.; Healthy RCE from baseline to follow-up vs. Healthy PL from baseline to follow-up
Difference in baseline microbiota composition between women with and without UUI and OAB	Baseline	The microbiota composition is analyzed using sequencing of bacterial DNA. Is there a difference in the urinary, vaginal and gut microbiota in women with and without urge urinary incontinence (UUI) and overactive bladder (OAB) at baseline?; Symptomatic PL baseline vs. Healthy PL baseline
Change from baseline microbiota composition in women suffering from UUI and OAB at three months follow-up	From baseline to three months follow-up	The microbiota composition is analyzed using sequencing of bacterial DNA. We are investigating the urinary, vaginal and gut microbiota. In women with urge urinary incontinence (UUI) and overactive bladder (OAB) receiving RCE (symptomatic RCE), a possible change in the urinary, vaginal and fecal microbiota composition from baseline to three month follow-up, compared to controls receiving placebo (symptomatic PL) are investigated.; Symptomatic RCE from baseline to follow-up vs. Symptomatic PL from baseline to follow-up

Secondary Outcome Measures

Name	Time	Method
Comparison of the urinary, vaginal, and fecal microbiota	Baseline	The microbiota composition is analyzed using sequencing of bacterial DNA. This composition is evaluated using alpha-diversity (measured based on number of unique bacteria as well as Shannon diversity and phylogenic diversity) and beta-diversity, as indicated by unifrac distance and bray-Curtis dissimilarity. Comparison of the urinary, vaginal, and fecal microbiota composition at baseline. All the different compartments are measured using the same Units of Measure.; Healthy PL baseline urinary vs. Healthy PL baseline vaginal vs. Healthy PL baseline gut
Change in urinary incontinence symptoms from baseline in women suffering from UUI and OAB at three months follow-up	From baseline to three months follow-up	Urinary incontinence symptoms are measured using the questionnaire International Consultation on Incontinence Questionnaire (ICIQ) Urinary Incontinence Short Form (ICIQ-UI-SF). Comparison of symptom scores in women with UUI and OAB before and after treatment with RCE compared to placebo.; Symptomatic RCE from baseline to follow-up vs. Symptomatic PL from baseline to follow-up
Change in overactive bladder symptoms from baseline in women suffering from UUI and OAB at three months follow-up	From baseline to three months follow-up	Overactive bladder symptoms are measured using the questionnaire International Consultation on Incontinence Questionnaire (ICIQ) Overactive Bladder (ICIQ-OAB). Comparison of symptom scores in women with UUI and OAB before and after treatment with RCE compared to placebo.; Symptomatic RCE from baseline to follow-up vs. Symptomatic PL from baseline to follow-up
Change in blood equol levels from baseline to three months follow-up	From baseline to three months follow-up	Blood equol levels are measured in nmol/L from plasma blood samples. Blood samples are taken at baseline before RCE and PL intake and after three months treatment.
Change in blood estrogen levels from baseline to three months follow-up	From baseline to three months follow-up	Blood estrogen levels are measured from serum blood samples. Blood samples are taken at baseline before RCE and PL intake and after three months treatment.
Change in gastrointestinal symptoms from baseline to three months follow-up	From baseline to three months follow-up	Gastrointestinal symptoms are measured using Rom IV criteria before and after RCE and PL intake.
Change in blood isoflavone levels from baseline to three months follow-up	From baseline to three months follow-up	Blood isoflavone levels are measured in ng/mL from plasma blood samples. Blood samples are taken at baseline before RCE and PL intake and after three months treatment.
Change in Irritable Bowel Syndrome Severity Score Scale from baseline to three months follow-up	From baseline to three months follow-up	Gastrointestinal symptoms are measured using the Irritable Bowel Syndrome Severity Score Scale before and after RCE and PL intake.
Change in Gastrointestinal Symptom Rating Scale from baseline to three months follow-up	From baseline to three months follow-up	Gastrointestinal symptoms are measured using the Gastrointestinal Symptom Rating Scale before and after RCE and PL intake.

Trial Locations

Locations (1)

North Denmark Regional Hospital (Vendsyssel Hospital); 🇩🇰 Hjørring, Denmark